Who Makes Ibogaine: From African Ritual to Modern Research
The question of who makes ibogaine has two answers. The iboga tree (Tabernanthe iboga) produces it naturally in West Central Africa, where it has been used in ritualistic ceremonies for centuries. But the story of who brought ibogaine to Western medicine, and who manufactures it today, begins with a New York heroin user in 1962 and continues through an evolving network of researchers, pharmaceutical companies, and underground providers.
According to a recent review, ibogaine is a naturally occurring hallucinogenic alkaloid originally used by West Central African tribes in spiritual ceremonies for centuries (Moore et al., 2026). Its transition from traditional medicine to Western research followed an unusual path, one that bypassed conventional pharmaceutical development entirely.
Howard Lotsof and the Ibogaine Discovery of 1962
The Howard Lotsof ibogaine discovery changed the trajectory of addiction research. Lotsof, then a 19-year-old heroin user in New York, took ibogaine recreationally in 1962. He noticed something unexpected. His withdrawal symptoms disappeared, and his craving for heroin diminished substantially.
This observation sparked decades of advocacy. Lotsof spent the rest of his life championing ibogaine as a treatment for opioid dependence, filing patents, and pushing for clinical research. His claims were anecdotal, but they attracted attention. As Moore et al. note, ibogaine's rise in popularity in the 1960s was fueled by reports from those with heroin addiction who claimed ibogaine stemmed their addiction (Moore et al., 2026).
In practice, this looked like grassroots research. Lotsof and a small network of collaborators conducted informal treatment sessions, documented outcomes, and presented findings at conferences. The medical establishment remained skeptical. Ibogaine was classified as a Schedule I substance in the United States in 1970, effectively halting domestic research for decades.
The History of Ibogaine in Scientific Research
The ibogaine history in formal science proceeded slowly after initial interest in the 1960s. Researchers in Europe and later in academic centers worldwide began investigating its pharmacology. The compound proved unusually complex.
Recent work has begun to clarify how ibogaine affects the brain. A 2026 study examined its action at serotonin synapses, finding that ibogaine modulates multiple transporters including the serotonin transporter (SERT) and vesicular monoamine transporter (VMAT2) (Hwu et al., 2026). This research was conducted in cell models, not humans, but it helps explain why ibogaine's effects differ from other psychedelics.
Ibogaine is now classified among psychoplastogens, compounds that rapidly promote neuroplasticity (Hoyer et al., 2026). This categorization places it alongside psilocybin, LSD, and MDMA as a potential tool for depression and related disorders. However, ibogaine's unique pharmacological profile, and its cardiac risks, distinguish it from these other substances.
Who Manufactures Ibogaine Today
The question of who manufactures ibogaine has no simple answer. No pharmaceutical company currently holds approval to sell ibogaine in major markets. The substance exists in a regulatory gray zone.
Supply comes from several sources. Some providers extract ibogaine from iboga root bark, the traditional source. Others synthesize it or its analogs in laboratories. The quality and purity vary considerably. This lack of standardization creates real risks for patients.
Where people get stuck is assuming ibogaine comes from a single regulated manufacturer. It does not. Treatment clinics in Mexico, Costa Rica, and other countries source ibogaine from various suppliers. Some use total alkaloid extracts from the plant. Others use purified ibogaine hydrochloride. The magnesium ibogaine formulation used in recent veteran studies combines ibogaine with pre- and post-treatment magnesium supplementation (Olash et al., 2026).
Researchers are also developing ibogaine analogs to improve safety profiles. One example is oxa-noribogaine, a synthetic derivative being studied for alcohol use disorder (Meinhardt et al., 2026). These analogs may eventually offer ibogaine-like benefits with reduced cardiac risks, though human data remains limited.
Who Owns Ibogaine: Patents and Regulatory Status
No single entity owns ibogaine. The compound itself cannot be patented, it occurs in nature. However, specific formulations, treatment protocols, and synthetic derivatives can be protected.
The regulatory picture is shifting rapidly. An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent therapies including ibogaine (Raffa et al., 2026). The FDA has issued Commissioner's National Priority Vouchers to psychedelic developers and cleared investigational new drug applications for related compounds.
This suggests ibogaine may move toward approved status in the coming years. A narrative review describes psychedelics as having reemerged as promising therapeutic tools in psychiatry after decades of regulatory marginalization (Marazziti et al., 2026). The authors note growing evidence of rapid and sustained effects on mood, cognition, and behavior, though they emphasize unmet clinical needs in treatment-resistant disorders.
Ibogaine Origin and Current Clinical Use
The ibogaine origin story spans continents and centuries. Traditional Bwiti practitioners in Gabon still use iboga root bark in initiation ceremonies. Western clinics now use purified ibogaine for addiction treatment. The gap between these contexts remains vast.
Clinical applications are expanding beyond opioid dependence. A case report documents sustained abstinence in a 30-year-old male with severe ketamine use disorder following ibogaine treatment (Pérez Rosal et al., 2026). The patient had a five-year history of severe polysubstance dependence including ketamine, cocaine, and alcohol.
Research with US Special Operations veterans has examined magnesium ibogaine for traumatic brain injury and PTSD. One study analyzed post-session narratives to characterize the subjective experience during treatment, finding reports of rapid clinical improvements (Olash et al., 2026). The therapeutic phenomenology during such healing had previously been unknown.
Evidence Gaps and Honest Limitations
Much of the ibogaine evidence base consists of case reports, small series, and uncontrolled studies. Large randomized controlled trials have not been completed. Cardiac safety remains a serious concern that requires medical screening and monitoring during treatment.
The question of who makes ibogaine responsibly remains unresolved. Without pharmaceutical-grade manufacturing standards, patients face uncertainty about purity and dosing. Treatment outside regulated settings carries inherent risks.
Practical Takeaway
If you are researching ibogaine, understand that no single company manufactures it to pharmaceutical standards. Treatment occurs primarily at international clinics operating under varying regulatory frameworks. The science is advancing, regulatory pathways are opening, but standardization lags behind interest. Verify the credentials of any provider, ask about cardiac screening protocols, and recognize that ibogaine treatment remains experimental despite decades of anecdotal reports and growing research interest.